ACM
IMMX icon

AIGH Capital Management’s Immix Biopharma IMMX Stock Holding History

AIGH Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,123,663
Closed -$1.67M – 42
2024
Q3 		$1.67M Sell
1,123,663
-283,017
-20% -$570K 0.47% 29
2024
Q2 		$2.79M Sell
1,406,680
-148,320
-10% -$341K 0.87% 23
2024
Q1 		$4.77M Buy
+1,555,000
New +$6.02M 1.43% 24

Other funds holding IMMX

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

AIGH Capital Management's IMMX Position: Q4 2024 in Review

AIGH Capital Management sold out of Immix Biopharma (IMMX) in Q4 2024, closing a stake of 1,123,663 shares — an estimated $1.67M sold.

AIGH Capital Management first reported a position in IMMX in Q1 2024 and held it in 3 quarters. The position peaked at $4.77M in Q1 2024. 23 funds tracked by Wall St. Rank hold IMMX as of Q4 2024.

  • AIGH Capital Management reported no remaining Immix Biopharma position as of Q4 2024 after selling out during the quarter.
  • AIGH Capital Management sold 1,123,663 Immix Biopharma shares in Q4 2024, an estimated $1.67M.
  • AIGH Capital Management first reported a position in Immix Biopharma in Q1 2024 and held it in 3 quarters.
  • AIGH Capital Management's Immix Biopharma position peaked at $4.77M in Q1 2024.
  • 23 funds tracked by Wall St. Rank held Immix Biopharma as of Q4 2024.

Based on AIGH Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.